Fairhaven Pro for men

ApprovedSmall molecule

HHamad Medical Corporation

Fairhaven Pro for men is one of 14 small molecule programs targeting Male Infertility. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Male InfertilityActive, not recruiting

Male InfertilityApproved

Active, not recruiting

Competition

Competitive Landscape

21 competitors in Male Infertility

#DrugCompanyPhaseTrials

Femara

Novartis

Approved

—2

Benemid

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Folvite

1 4

Arimidex

IIstituto Clinico Humanitas

Phase 3

1 5

Clomid

Prolia

2 7

Korean Red Ginseng

SShanghai Jiao Tong University School of Medicine

Approved

1 8

Accutane

CConrado Roberto Hoffmann Filho

Phase 2

1 9

Gonal-F

EMD Serono

Phase 2

—10

Deltavit

HHyundai Pharmaceutical Co., LTD.

Phase 2

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Male Infertility1 trial

Oxidative Stress In Semen And Male Infertility

Unknown status·HHamad Medical Corporation·Phase 4·NCT03464656·100 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Fairhaven Pro for men. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Fairhaven Pro for men compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Fairhaven Pro for men. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Hamad Medical Corporation company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: HHamad Medical Corporation

Fairhaven Pro for men

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Male Infertility1 trial

References

Drug Info

Quick Facts

Related News